BofA lowered the firm’s price target on United Therapeutics (UTHR) to $461 from $463 and keeps a Neutral rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- BTIG biotech analyst holds an analyst/industry conference call
- Buy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent Litigation
- Hold Rating for United Therapeutics’ Tyvaso Amid Mixed Trial Results and Real-World Applicability Concerns
- United Therapeutics price target raised to $580 from $560 at UBS
- Hold Rating Maintained for United Therapeutics’ Tyvaso Amid Competitive Landscape and Pending Data